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Effect of Levodopa-carbidopa Intestinal Gel
on Non-motor Symptoms in Patients with
Advanced Parkinson’s Disease
David G. Standaert, MD, PhD,1,* Ramon L. Rodriguez, MD,2 John T. Slevin, MD,3 Michael Lobatz, MD,4 Susan Eaton, PharmD,5
Krai Chatamra, PhD,5 Maurizio F. Facheris, MD,5 Coleen Hall, MS,5 Kavita Sail, PhD ,5 Yash J. Jalundhwala, PhD,5 Janet Benesh, BSMT5
Abstract: Background: Levodopa-carbidopa intestinal gel (LCIG; carbidopa-levodopa enteral suspension in
the United States), delivered via percutaneous gastrojejunostomy (PEG-J) and titrated in the inpatient setting,
is an established treatment option for advanced Parkinson’s disease (PD) patients with motor fluctuations.
However, long-term prospective data on the efficacy of LCIG on non-motor symptoms and the safety of
outpatient titration are limited.
Methods: In this 60-week, open-label phase 3b study, LCIG titration was initiated in an outpatient setting
following PEG-J placement in PD patients. The efficacy of LCIG on motor and non-motor symptoms, quality of
life, and safety was assessed.
Results: Thirty-nine patients were enrolled in the study and 28 patients completed the treatment. A majority
of patients (54%) completed outpatient titration within the first week of LCIG infusion. LCIG led to significant
reductions from baseline in Non-Motor Symptom Scale (NMSS) total score (least squares
mean  SE = 17.6  3.6, P < 0.001) and 6 of the NMSS domain scores (sleep/fatigue, attention/memory,
gastrointestinal tract, urinary, sexual function, miscellaneous) at week 12. These reductions were maintained
at week 60 with the exception of the urinary domain. “Off” time (4.9  0.5 hours/day, P < 0.001) and “On”
time without troublesome dyskinesia (4.3  0.6 hours/day, P < 0.001) were improved at week 60. Adverse
events (AEs) were reported in 37 (95%) patients.
Conclusions: LCIG treatment led to reductions in non-motor symptom burden and motor fluctuations in
advanced PD patients. The safety profile was consistent with previous studies that used inpatient titration
and outpatient titration did not appear to pose additional risk.
Levodopa-carbidopa is the most efficacious drug treatment for
Parkinson’s disease (PD). However, disease progression and pro-
longed use of standard oral formulations are associated with the
development of disabling motor complications that are refractory
to medication changes in a majority of levodopa-carbidopa-trea-
ted PD patients. Fluctuations in response are driven primarily by
non-physiologic pulsatile stimulation of striatal dopamine
receptors, which in turn are related partly to the progressive
degeneration of dopaminergic neurons, the short half-life of
levodopa, and increasingly irregular gastric emptying.1–7 These
fluctuations are also associated with a variety of non-motor
symptoms that substantially impact quality of life.8–10
Levodopa-carbidopa intestinal gel (LCIG; carbidopa-levodopa
enteral suspension in the United States) provides continuous
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intestinal levodopa infusion via percutaneous endoscopic gastro-
jejunostomy (PEG-J), and reduces fluctuations in levodopa
plasma concentrations.11,12 In prior phase 3 studies, including a
12-week, double-blind, double-dummy clinical trial,13 LCIG
reduced motor complications commonly associated with pro-
longed oral levodopa therapy in PD patients.13–15 Previously
published data from observational studies also indicate that
LCIG treatment is effective for the management of some non-
motor symptoms in PD patients refractory to oral levodopa
therapy.16,17 This open-label, baseline-controlled, phase 3b
study evaluated the long-term efficacy of LCIG on non-motor
symptoms in advanced PD patients over 60 week follow-up.
In the previous phase 3 studies participants were hospita-
lized for up to 14 days for PEG-J placement and LCIG dose
titration; however, current clinical practice does not require
routine hospitalization for these procedures. In this open-label
study, PEG-J placement was performed as per clinical practice
and LCIG dose titration was completed as an outpatient
procedure.
Methods
The efficacy of LCIG for the treatment of non-motor symp-
toms and safety of outpatient titration were assessed in advanced
PD patients experiencing motor fluctuations despite optimized
medical therapy in this open-label, phase 3b, 60-week study
(http://www.clinicaltrials.gov: NCT01736176). The study was
conducted at 12 specialized movement disorder centers in the
United States. The study protocol was approved by the institu-
tional review board/ethics committee at each study center and
all patients provided written informed consent.
Patients
Eligible participants were advanced PD patients, ≥30 years old,
levodopa-responsive, and diagnosed with idiopathic PD. Eligi-
ble participants also had motor fluctuations with ≥3 hours of
“Off” time per day at baseline despite individually optimized
PD therapy and had recognizable “Off” and “On” mobility
states, as observed by the study investigator and confirmed by
PD diary records. Key exclusion criteria included an unclear
PD diagnosis, a history of neurosurgical PD treatment, a Mini-
Mental State Examination score <24, or other evidence of sig-
nificant cognitive impairment.
Study Design
The study included a screening period (≤30 days), PEG-J place-
ment, outpatient LCIG titration, a 12-week primary LCIG
treatment period, and a 48-week, long-term LCIG-treatment
maintenance period (Fig. 1A). Following baseline evaluation, all
patients were converted from their carbidopa/levodopa doses
(immediate or extended release) to oral study drug (carbidopa/
levodopa 25/100 mg immediate release). All other anti-PD
medications were tapered-off/discontinued at the time of LCIG
initiation. Outside of the 16-waking hours of continuous LCIG
infusion, patients had the option to take oral carbidopa/levo-
dopa. Following the 12-week primary LCIG-treatment period,
additional concomitant anti-PD medications could be intro-
duced, if clinically indicated.
All patients received a 15 French Freka PEG tube and a 9
French Freka jejunal extension tube (Fresenius Kabi). The
PEG-J tube placement procedure occurred on study day 1 (D1)
by a gastroenterologist, surgeon, or interventional radiologist as
an outpatient procedure. At the discretion of the investigator or
the physician, patients could require in-patient (24–48 hours)
observation.
LCIG initiation and outpatient dose titration began within
5 days of PEG-J placement; outpatient summaries were based
on data observed by clinical nurse educators rather than study
investigators. LCIG was administered during waking hours; a
morning dose/bolus was followed by continuous infusion for
approximately 16 hours. The LCIG morning dose volume,
continuous infusion rate, and rescue dose volume were pro-
grammed on the infusion pump at clinic visits. Pump settings
were individually titrated based on clinical effect throughout
the study. The LCIG dose was considered optimized when the
programmed pump settings remained unchanged for 7 consecu-
tive days. Patients controlled the daily start and stop times of
infusions and could self-administer additional rescue doses, if
clinically indicated. Patients who completed their week 60
study visit before LCIG was commercially available to them
had the option to remain in the study with clinic visits every
12 weeks.
Efficacy
The primary efficacy outcome was the mean change in Non-
Motor Symptom Scale (NMSS) total score from baseline to
week 12. The NMSS assesses non-motor symptoms in PD, is
obtained through patient interview, and contains 30 questions
(grouped into 9 domains) that are scored with respect to sever-
ity. Total non-motor symptom burden is defined as mild
(NMSS total score = 1–15), moderate (16–40), severe (41–65),
and very severe (≥66).18 Secondary efficacy analyses included
the mean change from baseline at additional time points in
NMSS total score, the 9 NMSS domain scores, PD Symptom
Diary measures, the Unified Parkinson’s Disease Rating Scale
(UPDRS), the CANTAB spatial working memory (SWM)
assessment, and the Controlled Oral Word Association Test
(COWAT). The CANTAB and COWAT assessments were
not required to be performed. Health related quality of life
(HRQoL) outcomes were measured by the Parkinson’s Disease
Questionnaire-39 Item (PDQ-39) Summary Index (SI; score
range = 0–100, higher scores indicate worse HRQoL), and the
Patient Global Impression of Change (PGIC). For the PD
Symptom Diary, patients recorded their motor states every
30 minutes throughout the waking day over the 3 consecutive
days preceding each scheduled visit. Efficacy assessments were
collected at baseline (screening visit 2, before conversion to oral
levodopa monotherapy) and at preset intervals through
60 weeks.
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Safety
Treatment-emergent adverse events (AEs) were documented
throughout the study and included all AEs with onset on or
after the date of PEG placement and within 30 days of the
end of LCIG treatment. AEs were coded using the Medical
Dictionary for Regulatory Activities 18.1 (MedDRA)19 and
were tabulated by MedDRA preferred term (PT). Each safety
event was coded to only one PT. For each AE, the study
investigator rated it as ‘serious’ or ‘non-serious’ and deter-
mined its relationship to LCIG treatment. For the assessment
of treatment relationship, LCIG was considered as a therapeu-
tic system consisting of drug, devices, and placement proce-
dures. Causality assessments were to be made over the system
as a whole. AEs of special interest included gastro-intestinal
(GI) and GI procedure-related events, respiratory tract aspira-
tion events, weight loss events, cardiac fatalities, and polyneu-
ropathy events. AEs related to polyneuropathy were assessed
by a MedDRA PT search strategy defined by the polyneu-
ropathy and Guillain-Barre syndrome Standardized MedDRA
Queries (SMQs). A standardized panel of examination was
suggested to the investigator in the event that a patient devel-
oped signs and symptoms of polyneuropathy; patients with
polyneuropathy were treated at the investigators’ discretion.
To evaluate the effects of outpatient titration, AEs with onset
during the first 4 weeks were summarized separately. Clinical
laboratory, ECG, and vital signs were collected throughout
the study.
FIG. 1. (A) Study design and (B) Patient disposition. Abbreviations: S, screening visit; W, week. aLevodopa-carbidopa immediate release
tablets; bProcedure was performed as a standard outpatient procedure by gastrointestinal specialists; if the investigator or gastroin-
testinal specialist considered it medically necessary, patients were observed for up to 48 hours post-PEG-J placement in an inpatient
setting; c2 patients who had lack of efficacy as their primary reason for discontinuation had an adverse event as additional reason for
discontinuation.
MOVEMENT DISORDERS CLINICAL PRACTICE 831
doi:10.1002/mdc3.12526
D.G. STANDAERT ET AL. RESEARCH ARTICLE
Statistical Analysis
Efficacy analyses included all patients who received at least 1
LCIG infusion and had baseline and post-baseline observations
for at least one efficacy or health outcome measure (N = 38).
Safety summaries included all patients who underwent PEG-J
procedure (N = 39). Baseline was defined as the last non-miss-
ing observation that was on or before the date of the patient’s
first oral study drug dose (efficacy) or before the date/time of
the PEG-J procedure (safety). Final visit was defined as the last
non-missing observation that was ≤1 day after last LCIG infu-
sion (efficacy) or end of PEG-J exposure (safety). For efficacy
analyses, change from baseline was evaluated with a repeated
measures model that included fixed effects of study site and
visit, with baseline score as a covariate, and the baseline-by-visit
interaction (reported as the least-squares mean change  stan-
dard error). PD Diary data were normalized to a 16-hour wak-
ing day and averaged for the 3 days prior to each visit. Only
diaries with ≥12 hours of awake-time were included in the
analysis. “On” time without troublesome dyskinesia (TSD) was
defined as the sum of “On” time without dyskinesia and “On”
time with non-TSD.
Results
Of the 39 patients enrolled, 38 had successful PEG-J placement
and received LCIG infusion and 28 (72%) completed the study
(Fig. 1B). Eleven (28%) patients prematurely discontinued the
study. At baseline, patients had a mean  SD age of
64.3  10.2 years and the mean PD duration was
11.5  5.3 years. Patient demographics, PD characteristics, and
baseline assessments are summarized in Table 1.
Following PEG-J placement procedure, the mean  SD time
to patient discharge from the hospital/clinic was
20.4  14.6 hours (N = 30); 63% (n/N = 19/30) of patients
were discharged from the hospital within 24 hours. During out-
patient titration, 66% (n = 25) of patients received their first
LCIG dose within 24 hours of PEG-J placement; 90% (n = 34)
of patients had LCIG initiated within 48 hours. A majority of
patients (n = 20/37, 54%) reached an optimized dose within
the first week of LCIG infusion and only 2 (5.4%) patients
required more than 2 weeks to achieve dose optimization. One
patient discontinued treatment due to a non-procedure/device-
related AE with onset during the first 4 weeks of LCIG infu-
sion and 35 (92%) patients were still receiving LCIG infusions
at the 12-week primary endpoint. The mean  SD time of
patient exposure to LCIG was 427.2  188.7 days (range 2–
757 days; N = 38). The mean  SD time of patient exposure
to the LCIG delivery device was 427.5  190.8 days (range 1–
773 days; N = 39). Sixteen (42%) patients received concomitant
anti-PD medication during the 60-week treatment period and 7
(18%) of these patients received non-levodopa medication. The
most common concomitant, non-levodopa, anti-PD medication
during the 60-week treatment phase was entacapone (n = 4,
10.5%).
Efficacy
On average, patients had severe non-motor symptom burden at
baseline (NMSS total score, mean  SD = 48.3  35.6).18 At
the primary 12-week endpoint, LCIG-treated patients showed
significant reductions in NMSS total score with a least squares
(LS) mean  SE change of 17.6  3.6 (P < 0.001) (Fig. 2A).
NMSS total score remained significantly reduced at every study
visit from baseline through week 60 (Table 2). For patients
with severe non-motor symptom burden at baseline (baseline
NMSS total score > 40), the primary efficacy outcome was sim-
ilar to the overall patient population (NMSS total score, LS
mean change from baseline  SE: week 12 [n/N = 16/35]
33.4  6.2; week 60 [n/N = 12/28], 25.7  6.9). Five of
the 9 NMSS domain scores were significantly decreased com-
pared to baseline at week 60 (sleep/fatigue, P < 0.001; atten-
tion/memory, P = 0.013; gastrointestinal tract, P = 0.006;
sexual function, P = 0.021; miscellaneous, P = 0.003). The
NMSS urinary domain was significantly reduced compared to
baseline at week 12 (P = 0.044; Fig. 2B; Table 2). LCIG treat-
ment also led to significant improvements in the PDQ-39 SI at
every study visit through week 60 (Table 3). Additionally, a
majority of patients considered their status to be improved
(minimally improved, much improved, or very much improved)
at week 12 (PGIC, n/N = 30/38, 80%) and week 60 (PGIC,
TABLE 1 Baseline demographics and disease characteristics
Characteristic Value (N = 38)
Age, years, mean  SD [range] 64.3  10.2 [43-84]
Sex, female, n (%) 16 (41)
Race, white, n (%) 36 (92)
PD duration, years, mean  SD 11.5  5.3
NMSS total score,a mean  SD 48.3  35.6
NMSS domains,a mean  SD
Cardiovascular (including falls) 1.4  2.1
Sleep/Fatigue 11.6  9.2
Mood/Cognition 4.1  6.2
Perceptual Problems/
Hallucinations
1.9  3.8
Attention/Memory 4.6  6.4
Gastrointestinal Tract 5.3  6.1
Urinary 8.3  8.4
Sexual Function 2.7  3.6
Miscellaneousb 8.3  9.4
“Off” time,a hours
per day, mean  SD
6.6  1.6
“On” time with TSD,a
hours per day, mean  SD
0.9  1.8
“On” time without TSD,a
hours per day, mean  SD
8.4  2.2
PDQ-39 SI, mean  SD 34.7  13.0
PD medications reported at baseline in > 5 patients, n (%)
Levodopa 38 (100)
Amantadine 12 (32)
Pramipexole 10 (26)
Entacapone 8 (21)
Rotigotine 8 (21)
Ropinirole 6 (16)
NMSS, non-motor symptom scale; PD, Parkinson’s disease; PDQ-39
SI, Parkinson’s Disease Questionnaire 39-item Summary Index; SD,
standard deviation; TSD, troublesome dyskinesia
an = 38
bIncludes pain, taste/smell, weight, and excessive sweating
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n/N = 27/38, 71%); no patients considered their status as much
worse or very much worse at these time points. Changes in
neurocognition, measured using the CANTAB SWM and
COWAT, were not observed at week 12 or week 60 (week
60: CANTAB SWM, mean change from base-
line  SD = 0.6  7.7, P = 0.741, n = 18; COWAT,
0.8  2.3, P = 0.144, n = 18).
Significant and sustained reductions in mean hours of “Off”
time were observed through week 60 (Fig. 3 and Table 4). “Off”
time reductions were observed alongside increased “On” time
without TSD. “On” time without TSD was significantly
increased from baseline through week 60 (Fig. 3). “On” time
with TSD was stable through week 36 and increased significantly
at week 60 compared to baseline (P = 0.004). PD Diary asleep-
time was not significantly changed at week 60 (Table 4). LCIG-
treatment was also associated with significant and sustained
improvement in the UPDRS total and parts II, III, and IV scores
and UPDRS dyskinesia items 32, 33, and 34 (Table 3).
Safety
Overall, 37 (95%) patients experienced any AE and 35 (90%)
patients experienced an AE assessed by the investigator as
possibly related to LCIG (Table 5). The most common
AEs were procedural pain (patient incidence = 33%) and
stoma site infection (28%). AEs were generally mild to mod-
erate in severity, with 5 (13%) patients reporting a severe
AE. Severe AEs considered by the investigator to have a rea-
sonable possibility of being related to LCIG were: major
depression and suicidal ideation (n = 1), pneumonia and
orthostatic hypotension (n = 1), peritonitis (n = 1), and anxi-
ety (n = 1). Eight (21%) patients experienced a serious AE
(SAE; Table 5).
Polyneuropathy-related AEs were reported in 3 (8%) patients,
were mild in severity, and included loss of proprioception
(n = 1), peripheral neuropathy alone (n = 1), and peripheral
neuropathy with peripheral sensory neuropathy (n = 1). Prior
to LCIG initiation, patients reporting polyneuropathy-related
AEs were receiving between 1700 and 2400 mg daily levodopa
dose (oral carbidopa/levodopa 25/100 mg immediate release).
The reports of peripheral neuropathy alone and peripheral neu-
ropathy with peripheral sensory neuropathy were deemed by
the investigators to have a possible relationship to study drug.
The patient who experienced a loss of proprioception had a his-
tory of peripheral nerve disorder and vitamin B12 deficiency;
the event was determined by the investigator to have no rela-
tionship to study drug or oral carbidopa/levodopa immediate
release. No polyneuropathy-related AEs led to premature dis-
continuation of LCIG. Other AEs of special interest included
GI and GI procedure-related events (n = 28, 72%), weight loss
events (n = 8, 21%), and respiratory tract aspiration events
(n = 7, 18%).
During weeks 1–4, 22 (56%) patients experienced a GI-
related AE and 21 (54%) patients experienced a non-GI
related AE (Table 5). AEs that occurred in a higher percent-
age of patients during weeks 1–4, than during the longer
LCIG treatment period (weeks 5–60) included procedural pain
(weeks 1–4: 33%; weeks 5–60: 5.1%), anxiety (weeks 1–4:
13%; weeks 5–60: 10%) flatulence (weeks 1–4: 10%; weeks 5–
60: 0%) and stoma site irritation (weeks 1–4: 7.7%; weeks 5–
60: 2.6%). During weeks 1–4, 2 patients experienced SAEs
possibly related to LCIG (peritonitis [n = 1], internal hernia
[n = 1]).
Among the 5 patients (13%) who discontinued study drug
due to AE, 4 discontinued due to events considered by the
investigator to be possibly related to LCIG. One patient with a
baseline Mini Mental State Examination score of 24 discontin-
ued study drug on day 72 due to cognitive disorder with onset
on treatment day 3 that remained unresolved; 1 patient discon-
tinued due to stoma site pain with onset on day 130 that
resolved 8 days later; 1 patient discontinued due to a stoma site
infection with onset on day 255 that resolved 79 days later; 1
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FIG. 2. (A) Least squares mean change from baseline in the
NMSS total score and (B) Least squares mean change in the
NMSS domain scores at week 60. At week 60, n = 28. Error
bars indicate standard error. P-values from a repeated mea-
sure model that included fixed effects of study site and visit,
with baseline score as a covariate, and the baseline-by-visit
interaction indicate statistically significant mean change from
baseline scores of P < 0.05 (*), P < 0.01 (**) and P < 0.001
(***). Abbreviations: LS, least squares; NMSS, Non-Motor
Symptom Scale. aIncludes pain, taste/smell, weight, and
excessive sweating.
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patient discontinued due to the onset of pneumonia on day 255
that lasted for 15 days; another patient discontinued study drug
on day 178 due to events of congestive cardiac failure, acute
respiratory failure, and aspiration pneumonia following spinal
surgery. These events were considered to be unrelated to LCIG
by the study investigator and resulted in the patient’s death on
day 179.
Discussion
This open-label, phase 3b study evaluated the long-term effi-
cacy of LCIG for the treatment of non-motor symptoms and
the safety of outpatient titration in advanced PD patients. Con-
tinuous infusion of LCIG led to significant and clinically mean-
ingful20 reductions from baseline in non-motor symptom
severity at the primary 12-week endpoint and these reductions
were maintained through week 60. Importantly, LCIG treat-
ment reduced the mean non-motor symptom burden from a
severe level at baseline to a moderate level by week 4; this
moderate non-motor symptom burden was maintained through
week 60.18 NMSS domains that showed persistent improvement
over 60-weeks included the sleep/fatigue, attention/memory,
gastrointestinal tract, sexual function, and miscellaneous
domains. Disturbances in sleep/fatigue, which have a substantial
impact on quality of life,17 showed the greatest magnitude of
improvement at week 60 despite no statistically significant
change in absolute sleep time. While significant improvement
in the urinary domain at week 12 did not persist through week
60, previous studies on LCIG have demonstrated long-term
treatment-related improvements in this NMSS domain.16,17,21
In addition to the observed non-motor symptom improve-
ments, LCIG treatment also led to a significant and sustained
improvement in HRQoL. The improvements in non-motor
symptoms and HRQoL are consistent with previously published
long-term data on LCIG, including 12-month data from the
observational GLORIA study, which reported non-motor
symptom and HRQoL improvements in PD patients treated
with LCIG during routine care.16,17 Additionally, this study’s
TABLE 2 Least squares mean change from baseline on the Non-Motor Symptom Scale total score and domains
BL (n = 38) Week 12 (n = 35) Week 60 (n = 28)
Mean  SD Change from
BL LS Mean  SE
P Value Change from
BL LS Mean  SE
P Value
NMSS total scorea 48.3  35.6 17.6  3.6 <0.001 11.8 (4.0) 0.004
NMSS domainsa
Cardiovascularb 1.4  2.1 0.2  0.4 ns 0.5  0.4 ns
Sleep/Fatigue 11.6  9.2 6.0  1.2 <0.001 5.4  1.3 <0.001
Mood/Cognition 4.1  6.2 0.0  1.1 ns 0.5  1.2 ns
Perceptual problems/Hallucinations 1.9  3.8 0.5  0.4 ns 0.4  0.4 ns
Attention/Memory 4.6  6.4 2.1  0.8 0.010 2.2  0.9 0.013
Gastrointestinal tract 5.3  6.1 2.0  0.6 0.001 1.9  0.7 0.006
Urinary 8.3  8.4 2.2  1.1 0.044 0.1  1.2 ns
Sexual function 2.7  3.6 1.8  0.4 <0.001 1.1  0.5 0.021
Miscellaneousc 8.3  9.4 3.4  1.0 0.001 3.4  1.1 0.003
BL, baseline; LS, least squares; NMSS, non-motor symptom scale; ns, not significant; SD, standard deviation; SE, standard error.
aThe NMSS contains 30 questions grouped into 9 domains. Each question is scored with respect to severity (range from 0 = none to 3 =
severe) and frequency (range from 1 = rarely to 4 = very frequent). Item scores are calculated as the product of severity and frequency. A
negative NMSS score indicates improved symptom severity. NMSS total score and NMSS domains were analyzed by a mixed-effect model for
repeated measures using factors of study site, visit, and baseline, and the baseline-by-visit interaction.
bIncluding falls
cThe Miscellaneous domain includes questions on pain, change in the ability to taste and/or smell, weight change and excessive sweating.
TABLE 3 Least squares mean change from baseline in the UPDRS total score, UPDRS part II, III, and IV scores, and the PDQ-39 Summary
Indexa
Baseline
N = 37
D7
N = 36
Week 12
N = 34
Week 36
N = 32
Week 60
N = 28
UPDRS total scoreb 43.3  17.8 8.8  1.5*** 11.4  1.7* 7.1  1.9*** 7.7  2.3**
UPDRS I 1.6  1.6 0.6  0.2** 0.3  0.3 0.3  0.3 0.1  0.3
UPDRS II 16.7  6.5 4.8  0.7*** 5.5  0.9*** 4.2  0.9*** 4.7  0.9***
UPDRS III 25.0  13.2 3.5  1.2** 5.6  1.2*** 2.6  1.5 3.6  1.5**
UPDRS IVc 8.7  3.0 2.7  0.5*** 3.5  0.4*** 3.5  0.4*** 2.9  0.6***
UPDRS dyskinesia itemsd 3.0  2.1 1.1  0.4** 1.1  0.3*** 1.1  0.3*** 0.6  0.4
PDQ-39 SI 34.7  13.0 4.8  1.8* 11.2  2.8*** 9.1  2.2*** 10.2  2.6***
D, day; LS, least squares; PDQ-39 SI, Parkinson’s Disease Questionnaire 39-tem Summary Index; UPDRS, Unified Parkinson’s Disease Rating
Scale; Values compared to baseline with paired t-test, P < 0.001 (***), 0.01 (**), 0.05 (*).
aAll values depict LS mean  standard error with the exception of the baseline values which represent the mean  standard deviation.
bUPDRS was collected in the “On” state.
cBaseline, n = 38; D7, n = 37; Week 12, n = 35.
dItems 32, 33, 34.
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results are consistent with a prospective observational study that
reported improvement in non-motor symptom severity with
LCIG treatment that was superior to the effects observed with
apomorphine.21
Reduced non-motor symptom burden occurred alongside
sustained improvements in motor symptoms, including a signifi-
cant and clinically meaningful decrease in “Off” time through
week 60.22 Notably, reduced “Off” time was observed together
with a significant increase in “On” time without TSD. These
data indicate that reduction in “Off” time was not achieved at
the expense of increasing dyskinesia, an important consideration
in efforts to improve patients’ quality of life.23
A secondary objective of this study was to evaluate the safety
of outpatient LCIG titration, an approach that is more reflective
of current clinical practice. The data indicate the success of out-
patient titration, with 90% of patients beginning LCIG infusion
within the first 48 hours after PEG-J placement and a majority
of patients reaching LCIG dose optimization within one week
of their first LCIG infusion. The safety results also suggest that
outpatient LCIG titration was generally well tolerated. The per-
centage of patients in the current study that experienced an AE
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FIG. 3. Least squares mean change from baseline in PD
Symptom Diary measures over time. Error bars indicate stan-
dard error. P-values from a repeated measure model that
included fixed effects of study site and visit, with baseline
score as a covariate, and the baseline-by-visit interaction
indicate statistically significant mean change from baseline
to final scores of P < 0.01 (**) and P < 0.001 (***). Abbrevia-
tions: BL, baseline; LS, least squares; PD, Parkinson’s disease;
TSD, troublesome dyskinesia
TABLE 4 Least squares mean change from baseline in the PD diary measuresa
Baseline
N = 38
D7
N = 34
Week 12
N = 32
Week 36
N = 31
Week 60
N = 21
‘Off’ time 6.6  1.6 1.4  0.4*** 4.1  0.4*** 3.8  0.4*** 4.9  0.5***
‘On’ time without TSD 8.4  2.2 1.0  0.5* 3.7  0.5*** 3.8  0.5*** 4.3  0.6***
‘On time with TSD 0.9  1.8 0.3  0.3 0.2  0.3 0.1  0.3 1.2  0.4**
Absolute asleep time 7.5  1.8 0.0  0.2 0.2  0.2 0.1  0.3 0.3  0.3
D, day; LS, least squares; PD, Parkinson disease; TSD, troublesome dyskinesia; Values compared to baseline with paired t-test, P < 0.001
(***), 0.01 (**), 0.05 (*).
aNormalized to 16-hour waking day; All values depict least squares mean  standard error with the exception of the baseline values which
represent the mean  standard deviation.
TABLE 5 Safety summary
Number of Patients
(% of N = 39)
Any adverse event (AE) 37 (95)
During Weeks 1-4 28 (72)
Any GI eventa 28 (72)
During Weeks 1-4 22 (56)
Any non-GI event 37 (95)
During Weeks 1-4 21 (54)
Any serious AE (SAE) 8 (21)
During Weeks 1-4 3 (8)
Any AE leading to a discontinuation 5 (13)
During Weeks 1-4 1 (3)
Death 1 (3)
During Weeks 1-4 0
AEs Occurring in ≥ 10% Patients
Procedural pain 13 (33)
Stoma site infection 11 (28)
Stoma site pain 9 (23)
Anxiety 8 (21)
Stoma site erythema 8 (21)
Fall 7 (18)
Weight decreased 7 (18)
Urinary tract infection 6 (15)
Orthostatic hypotension 5 (13)
Excessive granulation tissue 4 (10)
Flatulence 4 (10)
Nausea 4 (10)
Stoma site irritation 4 (10)
Vitamin B6 deficiency 4 (10)
SAEs Occurring in Any Patient
Acute respiratory failure 1 (3)
Anxiety 1 (3)b
Atrial fibrillation 1 (3)b
Aspiration pneumonia 1 (3)
Basal cell carcinoma 1 (3)
Congestive cardiac failure 1 (3)
Internal hernia 1 (3)b
Major depression 1 (3)b
Osteoarthritis 1 (3)
Peritonitis 1 (3)b
Radiculopathy 1 (3)
Respiratory distress 1 (3)b
Sedation 1 (3)
Suicidal ideation 1 (3)b
AE, adverse event; GI, gastrointestinal; SAE, serious adverse event.
aGI events includes all MedDRA preferred terms in the GI and GI
procedure related events query.
bInvestigator determined SAE had a reasonable possibility of being
related to treatment
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during the first 4-weeks following PEG-J placement (71.8%)
was lower than previously reported in other phase 3 LCIG
studies that utilized inpatient titration, including a 12-week,
double-blind, placebo-controlled, double-dummy clinical trial
(% of patients with AE during weeks 1–4 = 86.5%) and a 12-
month open label study (% of patients with AE during weeks
1–4 = 78.4%).24 A similar pattern was observed for SAEs, with
a substantially lower percentage of patients reporting a SAE
(7.7%) during weeks 1–4 post-PEG-J placement in the current
study compared to previous phase 3 studies using inpatient titra-
tion (% of patients with SAE during weeks 1–4: double-blind
study = 13.5%, open-label study = 13.5%).24 Additionally, the
discontinuation rate during the first 4-weeks following PEG-J
placement (2.6%) was comparable to the week 1–4 discontinua-
tion rate reported in an integrated analysis of previous phase 3
studies (2.0%).25 In the current study, only one patient discon-
tinued treatment due to an event with onset during the first 4-
weeks of LCIG infusion and the reason for discontinuation was
unrelated to the procedure/device.
The safety results over the course of the entire study also
speak to the general success of outpatient titration. While the
discontinuation rate (28%) and rate of discontinuations due to
AE (13%) over the entire study course were higher than previ-
ous phase 3 studies (overall phase 3 discontinuation
rate = 17%,25 discontinuation due to AE rate from Fernandez
et al. [2015] = 8%15), study discontinuations were distributed
over the entire course of the study and likely not influenced by
outpatient titration, which was completed within the first 4-
weeks of treatment. The percentage of patients that experienced
≥1 AE (95%) and the severity of these AEs (mostly mild/mod-
erate) were comparable to previous reports.15,25 Compared to
previous phase 3 studies, the percentage of patients who experi-
enced ≥ 1 GI-related AE was slightly lower in the current study
(56% vs. 62%).15 Polyneuropathy was identified in 3 (8%)
patients, was mild in severity, non-serious, and did not lead to
premature discontinuation for any patient. Polyneuropathy-
related events occurred at a rate that is consistent with reports
in the literature for PD patients receiving levodopa therapy as
well as an integrated analysis of safety from previous phase 3
studies on LCIG.26 Also important to note is that one patient
reporting a polyneuropathy-related AE had a previous history of
peripheral nerve disorder. Serious AEs (21%) did not indicate
any new safety concerns for LCIG.
Limitations of this study include its open-label design and
lack of a control group, which is important to consider, as treat-
ment-related improvements in non-motor symptoms have been
associated with a strong placebo effect in recent literature.27
However, the long-term follow-up, magnitude of observed
change in non-motor symptom burden, and the similarity of
the current findings to previous data on LCIG efficacy for the
treatment of non-motor symptoms in advanced PD patients, are
strengths of the current study.
In summary, LCIG demonstrated sustained and clinically
meaningful reductions in non-motor symptom burden and
improvements in quality of life in advanced PD patients with
motor fluctuations over a 60-week treatment period. Also,
LCIG was generally well tolerated, supporting the established
profile of LCIG and the safety of outpatient titration.
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